BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by C WorldWide Group Holding A S

C WorldWide Group Holding A S increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 12.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 267,851 shares of the biotechnology company’s stock after acquiring an additional 30,000 shares during the period. C WorldWide Group Holding A S’s holdings in BioMarin Pharmaceutical were worth $15,918,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of BMRN. NewEdge Advisors LLC increased its stake in BioMarin Pharmaceutical by 11.5% during the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 388 shares during the period. Empowered Funds LLC increased its stake in BioMarin Pharmaceutical by 207.4% during the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock valued at $850,000 after buying an additional 8,112 shares during the period. Focus Partners Wealth increased its stake in BioMarin Pharmaceutical by 70.2% during the 1st quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock valued at $835,000 after buying an additional 4,876 shares during the period. Sivia Capital Partners LLC increased its stake in BioMarin Pharmaceutical by 33.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 1,102 shares during the period. Finally, Invesco Ltd. increased its stake in BioMarin Pharmaceutical by 23.5% during the 2nd quarter. Invesco Ltd. now owns 618,835 shares of the biotechnology company’s stock valued at $34,017,000 after buying an additional 117,617 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Activity

In other news, EVP Gregory R. Friberg sold 6,326 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the transaction, the executive vice president owned 37,578 shares in the company, valued at approximately $2,268,959.64. This trade represents a 14.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Charles Greg Guyer sold 16,486 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the transaction, the executive vice president owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. This trade represents a 17.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

BMRN has been the topic of several research analyst reports. Sanford C. Bernstein lowered their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Stifel Nicolaus set a $68.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, February 24th. Piper Sandler lowered their target price on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Barclays raised their target price on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Finally, Canaccord Genuity Group raised their target price on shares of BioMarin Pharmaceutical from $104.00 to $116.00 and gave the company a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $90.86.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $54.06 on Monday. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $66.28. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. The company has a 50-day moving average of $56.38 and a 200-day moving average of $56.34. The firm has a market cap of $10.45 billion, a price-to-earnings ratio of 39.46, a price-to-earnings-growth ratio of 0.40 and a beta of 0.23.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.